XDH and gout: Per pegloticase indication, the PROTECT clinical trial enrolled KT patients with chronic gout who have failed to normalize sUA and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.